Becton Dickinson and Co
NYSE:BDX

Watchlist Manager
Becton Dickinson and Co Logo
Becton Dickinson and Co
NYSE:BDX
Watchlist
Price: 224 USD -0.64% Market Closed
Market Cap: 64.7B USD
Have any thoughts about
Becton Dickinson and Co?
Write Note

Becton Dickinson and Co
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Becton Dickinson and Co
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Becton Dickinson and Co
NYSE:BDX
Other Equity
$25.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Other Equity
-$128m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Edwards Lifesciences Corp
NYSE:EW
Other Equity
-$247.5m
CAGR 3-Years
-16%
CAGR 5-Years
-10%
CAGR 10-Years
-13%
Stryker Corp
NYSE:SYK
Other Equity
-$545m
CAGR 3-Years
13%
CAGR 5-Years
0%
CAGR 10-Years
-21%
Abbott Laboratories
NYSE:ABT
Other Equity
-$8.1B
CAGR 3-Years
4%
CAGR 5-Years
-1%
CAGR 10-Years
-11%
Intuitive Surgical Inc
NASDAQ:ISRG
Other Equity
$23.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
37%
No Stocks Found

Becton Dickinson and Co
Glance View

Market Cap
64.7B USD
Industry
Health Care

Becton Dickinson and Co. (BD) is a global leader in the medical technology sector, with a rich history tracing back to its founding in 1897. The company specializes in the development, manufacturing, and distribution of a wide array of medical devices, instrument systems, and reagents that are essential in hospitals and laboratories. BD's products play a pivotal role in improving patient outcomes by enhancing the accuracy of diagnostics and facilitating efficient pharmaceutical delivery. With a commitment to innovation, BD invests significantly in research and development, ensuring it remains at the forefront of advanced technology in healthcare, which resonates well with investors seeking sustainable growth in a resilient industry. The company's diverse portfolio spans three main segments: BD Medical, BD Life Sciences, and BD Biosciences, enabling it to tap into multiple revenue streams while addressing critical healthcare needs worldwide. BD's strategic focus on expanding its presence in emerging markets, coupled with its robust pipeline of new products, positions it favorably for future growth. Additionally, BD’s commitment to operational excellence and cost management bolsters its profitability and shareholder value. For investors, BD offers a compelling opportunity as it navigates the evolving landscape of healthcare, characterized by increasing demand for high-quality medical solutions and a growing emphasis on personalized medicine. As the company continues to deliver innovative products and services while maintaining strong financial fundamentals, it remains a key player to watch in the dynamic world of medical technology.

BDX Intrinsic Value
290.39 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Becton Dickinson and Co's Other Equity?
Other Equity
25.9B USD

Based on the financial report for Sep 30, 2024, Becton Dickinson and Co's Other Equity amounts to 25.9B USD.

Back to Top